Aug 5 (Reuters) - Quantum Biopharma Ltd QNTM.CD:
QUANTUM BIOPHARMA ANNOUNCES POSITIVE RESULTS OF THE CLINICAL STUDY REPORT (CSR) FOR THE PHASE 1 MULTIPLE ASCENDING DOSE (MAD) CLINICAL TRIAL OF EXPERIMENTAL MULTIPLE SCLEROSIS DRUG LUCID-21-302 (LUCID-MS)
QUANTUM BIOPHARMA LTD - CSR FINDS NO SAFETY CONCERNS FOR LUCID-MS